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SURGERY: CAUTION ADVISED
To the Editor:
We recently read the interesting
study by McKellar and associates1
evaluating the effectiveness of dabiga-
tran for thromboprophylaxis after im-
plantation of mechanical heart valves.
Using a heterotopic aortic valvemodel,
the authors randomized 30 swine to
receive dabigatran, enoxaparin, or no
anticoagulation after implantation of
a mechanical valve conduit. At 30
days, McKellar and associates1 re-
ported that dabigatran reduced throm-
bus and platelet deposition on the
mechanical valve leaflets without an
increase in adverse events.
Several new oral direct thrombin in-
hibitors are being evaluated as alterna-
tives for long-term anticoagulation
because of the widely known difficul-
ties associatedwithwarfarin, including
its long half-life and unpredictable
dose response. Compared with warfa-
rin, dabigatran has no food or drug in-
teractions, has a rapid onset of action,
and does not require blood monitor-
ing.2,3 Paradoxically, while lauded for
its ease of use, the management of
patients receiving dabigatran may be
extremely challenging in the setting
of active bleeding and coagulopathy.
McKellar and colleagues1 claim that,
in contrast to warfarin, dabigatran
‘‘could prove safer should emergency
surgery be needed.’’ We respectfully
disagree with this statement. There is
no known antidote available for dabi-
gatran. Vitamin K and fresh frozen
plasma are ineffective, and dialysis
maybe the onlymeans available to rap-
idly reverse the anticoagulant effects of
dabigatran.4,5
We recently prescribed dabigatran
to a 74-year-old woman after coronary1288 The Journal of Thoracic andartery bypass graft surgery. The pa-
tient had a history of atrial fibrillation
and had previously refused warfarin
therapy. After surgery, she continued
to refuse warfarin, but she agreed to
take dabigatran to reduce the risk of
stroke and systemic embolism.6 Dabi-
gatran was initiated on postoperative
day 3 using the lowest possible dose
(75mg twice daily), given the patient’s
frailty and mild renal insufficiency.
She was monitored in the hospital for
6 additional days before transfer to
a rehabilitation facility. A chest x-ray
film before discharge noted a very
small left pleural effusion. Twodays af-
ter transfer, the patient returned to hos-
pital with a massive left hemothorax
and gastrointestinal bleeding. She was
treated with intubation for respiratory
distress and placement of a left thora-
costomy tube, draining more than 2 L
of blood. The patient had evidence of
a severe coagulopathy, with an interna-
tional normalized ratio of 21.5 and
a partial thromboplastin time of 161.2.
Tomanage the bleeding, we instituted
emergency dialysis, successfully cor-
recting the coagulopathy. After 2 di-
alysis treatments, the international
normalized ratio and partial thrombo-
plastin time were reduced to 1.9 and
47.4, respectively, and the chest and
gastrointestinal bleeding had sub-
sided. The patient made a miraculous
recovery and was discharged back to
rehabilitation 2 weeks later without
anticoagulation therapy.
McKellar and associates1 are to be
congratulated for their novel study.
Their animal model data suggest that
dabigatran may have a role in the
thromboprophylaxis of mechanical
valves. Wewould be intrigued to learn
whether they have had any clinical ex-
perience using dabigatran in patients
undergoing cardiac surgery, either
for the thromboprophylaxis of me-
chanical valves or for the anticoagula-
tion of atrial fibrillation. Although our
experience is limited to a single case,
the outcome was nearly fatal. We
would therefore strongly advise cau-
tion when prescribing dabigatranCardiovascular Surgery c November 20early after cardiac surgery, at least un-
til additional clinical experience
accrues.
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ARTERY OR CONUS ARTERY
WITH SEPARATE ORIFICE?
To the Editor:
In their recent Cardiothoracic Im-
aging article, Chen, Chien, and Lee1
have applied the term ‘‘double right
coronary artery’’1 (RCA) in a debat-
able way.
The anatomic nomenclature for the
situation they have described has
been better termed ‘‘the conus artery:
a third coronary artery’’2; ‘‘conus cor-
onary artery with aortic origin’’3; or,
more appropriately, ‘‘conus artery
with separate orifice,’’ coded as11
Letters to the Editor09.42.18 in the International Pediatric
and Congenital Cardiac Code.4 This
variation appears in 45% of human
hearts.2,3
The double RCA is an extremely
uncommon coronary artery anomaly
with 2 RCAs, coursing toward the
right atrioventricular groove, originat-
ing marginal branches, terminating by
giving off the posterior descending ar-
tery in the posterior interventricular
groove. It is predominantly seen in
male patients and might originate
from either single or separate ostia.5
We think it is important to standard-
ize the nomenclature in order to have
the correct identification of anatomic
structures.
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REGARDING BACKGROUND
MORTALITY IN
OBSERVATIONAL STUDIES
To the Editor:
We read with great interest the arti-
cle ‘‘Aortic Valve Replacement: Re-
sults and Predictors of Mortality
From a Contemporary Series of 2256The JournalPatients,’’ by Di Eusanio and associ-
ates,1 in a recent issue of the Journal.
We congratulate Di Eusanio and asso-
ciates on their favorable results after
aortic valve replacement (AVR) in oc-
togenarians and on the identification
of predictors for postoperative mortal-
ity. Some methodologic issues exist,
however, concerning the comparison
of patient survivals with that of a refer-
ence population. The investigators
used a static method to compare the
3-year survival for octogenarians who
had undergone AVR with the expected
survival of an age- and sex-matched re-
gional population and concluded that
the survivals were statistically similar
(P ¼ .157).
Intuitively, it would seem apparent
that survival after AVR is unlikely to
be comparable to that of the general
population. Patients undergoing heart
valve replacement are vulnerable to
both valve-related and non–valve-re-
lated events. In addition, the left ven-
tricle in a patient with aortic valve
disease is characterized by progres-
sive accumulation of interstitial myo-
cardial fibrosis and impairment of
myocyte ultrastructure, leading to de-
creased survival. Aortic stenosis has
been shown to be an inflammatory
process associated with histopatho-
logic changes in the valve leaflets
that are similar to those seen in other
atherosclerotic diseases, and the pres-
ence of calcific valve disease is associ-
ated with hypertension, diabetes, and
the metabolic syndrome.2 A survival
comparable to that of the general pop-
ulation can therefore only be achieved
by strict selection of patients undergo-
ing AVR, which is the case in the
study by Di Eusanio and associates.1
The major shortcoming in the static
comparison method is that a dynamic
cohort, in this case the octogenarian
study population, is being compared
with a static reference cohort from
the regional life tables. Changes in
the patient group caused by with-
drawal at different times make the
study cohort dynamic and necessitate
a rate adjustment to make theof Thoracic and Cardiovascular Surgercomparison with the reference cohort
more accurate.3-5 Rate adjustment
can be achieved by matching the
reference cohort with respect to age,
sex, and calendar time at every
moment that an event occurs in the
study population. The benefit of
treatment is overestimated when this
mechanism is not taken into account.
It would be interesting if Di Eusanio
and associates were to compare the
survival of the patient group with
that of the age-, sex-, and calendar
time–matched regional population by
means of rate adjustment.
Matching should be performed not
only for age and sex but also for other
important demographic indicators,
such as ethnicity and socioeconomic
class.5 Unfortunately, these data are
seldom available, and consequently
comparisons with the general popula-
tion should be interpreted carefully.
Finally, we question some of the
numbers and the corresponding fig-
ures in the article. Figure 1 in the
article shows a significantly lower sur-
vival of patients in New York Heart
Association functional class III or IV
than of those in class I or II (P <
.001), whereas in the text a nonsignifi-
cant P value of .157 is stated. In addi-
tion, Figure 3 in the article shows
a 2-year survival of 87.4% for the
AVR after 80 years of age group,
whereas in the text a 2-year survival
of 89.7% is mentioned.
In our opinion, comparison with
a reference group should be handled
with caution. We suggest the develop-
ment of specific guidelines to compare
an accurately matched population to
ensure that all factors are taken into
account and that the comparison per-
formed is methodologically correct.
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